实体瘤放射免疫治疗  

Radioimmunotherapy in solid tumors

作　　者：翁丁虎 秦赛梅 安锐[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院核医学科、湖北省分子影像重点实验室,武汉430022

出　　处：《中华核医学与分子影像杂志》2018年第2期134-137,共4页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：国家自然科学基金（81371599）

摘　　要：放射免疫治疗（RIT）因具有较好的靶向性并可最大限度减少对非靶器官的放射性损伤而被用于肿瘤的辅助和（或）巩固治疗。以前实体瘤RIT发展缓慢，但近来α核素的应用、抗体制备技术的进步、新治疗策略的实施等使得实体瘤RIT得到了较快发展，其在清除肿瘤微小残留病灶中具有潜在优势。Radioimmunotherapy （RIT） is often used as an adjuvant therapy or consolidation thera- py for cancer due to its relative high specificity and minimized radiation damage to non-targeted organs. The progress of RIT in solid tumors was slow, however, it has been developed quickly recently especially in elimination of residual micro-tumor lesions due to the application of α radionuclide, the progress in antibody preparation, and the implementation of new therapeutic strategies.

关 键 词：放射免疫疗法 实体瘤 发展趋势 

分 类 号：R730.51[医药卫生—肿瘤]